Global Trends in Hematopoietic Cell Transplantation.
Authors: Baldomero Helen , Aljurf Mahmoud , Bouzas Luis Fernando , Gratwohl Alois , Kodera Yoshihisa , Lipton Jeff H , Madrigal J. Alejandro , Minako Lida , Novitzky Nicolas , Pasquini Marcelo C , Passweg Jakob R. , Seber Adriana , Szer Jeffrey , Niederwieser Dietger 
Published: October 2019

Abstract
Abstract 3143
Hematopoietic cell transplantation (HCT) is the treatment of choice for many patients with malignant and non-malignant disorders. Transplant practices have evolved allowing patients previously not otherwise candidates to receive this procedure. Activity surveys and registries play an essential role in the success of HCT, by tracking activities, identifying areas of need and through clinical research to continue improving patient outcome. Because of the need of matched donors, ethnic characteristics and legal requirements HCT has acquired a global dimension. In the current analysis the Worldwide Blood and Marrow Transplantation network (WBMT) reports the global activities, indications and trends for the years 2006 to 2008.
The survey consisted of activities reported to the WBMT from international societies members (EBMT, CIBMTR, APBMT, EMBMT, ABMTRR), national registries (SBTMO) and also directly from transplant centers in regions were no societies are established. Annual transplant center specific activities were from 1327 transplant centers in 71 countries in 2006. The number of participating centers increased to 1382 and 1407 in 2007 and 2008, respectively. Annual number of transplants steadily increased from 46,563 in 2006 to 48,709 and 51,536 in 2007 and 2008. When analyzing the median number of transplants/year performed at each center the corresponding annual activity was 38 (range 3–180), 46 (3–421) and 48 (1–389), suggesting that the increment in transplant activity is not only related to higher number of reporting centers.
The highest increase in total HCT over two years was observed in the Asia Pacific region (38.6%) followed by the East Mediterranean region (19.4%), Europe (5.6%) and the U.S. (4.5%). An absolute increase of autologous and allogeneic was observed over the three year period with more autologous (55%) than allogeneic (45%) HCT reported, however the increase was less in autologous (+5.0%) when compared to allogeneic (+17.9%). Among indications for allogeneic HCT, acute leukemias (AML +23%; ALL +27%), myelodysplasia (MDS +26%), chronic lymphocytic leukemia (CLL +24.6%) nonmalignant diseases (NMD +23.6%) and bone marrow failure disorders (BMF +21.2%) significantly increased during the study period. Slower increase was reported for lymphoproliferative disorders (LPD +6%) and a clear decrease for chronic myelogenous leukemia (CML -17%) and solid tumors (−13.3%). Among autologous HCT indications autoimmune diseases (+24.5%), PCD (+9.8%) and LPD (+7.5%) increased during the period. A negative trend was seen in autologous HCT for solid tumors (−2.4%), ALL (−22.0%), AML (−9.0%), CLL (−52.0%) and CML (−57.1%).
These data show the trend and activity for autologous and allogeneic HSCT worldwide. There is a clear increase in activity especially in acute and chronic (except CML) leukemias for allogeneic HST and for autoimmune diseases, LPD and PCD in autologous HCT. Monitoring global transplant practices is an important activity for WBMT in order for capacity planning of HCT donor pool worldwide and to promote the field by expanding access to transplantation at regions in need.

Disclosures:
No relevant conflicts of interest to declare.